Comparison of Oral Insulin Spray and Subcutaneous Regular Insulin at Mealtime in Type 1 Diabetes

Guevara‐Aguirre, Jaime; Guevara‐Aguirre, Marco; Saavedra, Jeannette; Bernstein, Gail A.; Rosenbloom, Arlan L.

doi:10.1089/dia.2006.0019

Cited by 21 publications

(17 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No deaths or serious adverse events occurred (Supplementary Table 4). Guevara-Aguirre et al reported total hypoglycemic event in their study [41]. However, no subject requiring medical intervention for hypoglycemic treatment was noticed.…”

Section: Safetymentioning

confidence: 79%

“…So it is necessary to consider time of oral insulin administration as an important variable and study it Kipnes et al 2003 Fair GuevaraAguirre. et al 2004 Fair Pozzilli et al 2005 Poor Fair Guevara-Aguirre et al 2007 Fair Schwartz et al 2008 Good Luzio et al 2010 Good Annabestani et al 2010 Fair Kapitza et al 2010 Fair Khalili et al 2010 Fair Generex report2013 Good precisely in future investigations. Detailed pharmacokinetic and pharmacodynamic studies are necessary to obtain the best time interval between oral insulin administration and taking a meal.…”

Section: Discussionmentioning

confidence: 99%

“…2) [19,41,42]. Oral spray and SC insulin decreased 1-h postprandial blood glucose indifferently [mean difference (MD) −1.962, 95 % confidence interval (95 % CI) −4.837 to 0.803, P = 0.164; three trials; heterogeneity I 2 = 96.3 %, P < 0.001].…”

Section: Fasting and Postprandial Glucosementioning

confidence: 99%

“…2) [19,20,[40][41][42]. Meta-analysis showed that there was no difference between oral insulin and SC insulin in 2 …”

Section: Fasting and Postprandial Glucosementioning

confidence: 99%

“…2 ) [40,41,43]. Metaanalysis showed that the HbA 1c decreased with oral insulin compared to baseline [mean difference (MD) −0.141 95 % confidence interval (95 % CI) −0.393 to 0.111, P = 0.276; 3 trials; heterogeneity I 2 = 0.0 %, P = 0.692].…”

Section: Hba 1cmentioning

confidence: 99%

See 4 more Smart Citations

Efficacy and safety of oral insulin compared to subcutaneous insulin: a systematic review and meta-analysis

Akbari

Hendijani

Feizi

et al. 2015

J Endocrinol Invest

View full text Add to dashboard Cite

show abstract

Section: Safetymentioning

confidence: 79%

Section: Discussionmentioning

confidence: 99%

Section: Fasting and Postprandial Glucosementioning

confidence: 99%

“…2) [19,20,[40][41][42]. Meta-analysis showed that there was no difference between oral insulin and SC insulin in 2 …”

Section: Fasting and Postprandial Glucosementioning

confidence: 99%

Section: Hba 1cmentioning

confidence: 99%

See 3 more Smart Citations

Efficacy and safety of oral insulin compared to subcutaneous insulin: a systematic review and meta-analysis

Akbari

Hendijani

Feizi

et al. 2015

J Endocrinol Invest

View full text Add to dashboard Cite

show abstract

Strategies in synthetic design and structure–activity relationship studies of novel heterocyclic scaffolds as aldose reductase‐2 inhibitors

Yahya

Haider

Pathak

et al. 2022

Archiv der Pharmazie

View full text Add to dashboard Cite

Heterocyclic scaffolds of natural as well as synthetic origin provide almost all categories of drugs exhibiting a wide range of pharmacological activities, such as antibiotics, antidiabetic and anticancer agents, and so on. Under normal homeostasis, aldose reductase 2 (ALR2) regulates vital metabolic functions; however, in pathological conditions like diabetes, ALR2 is unable to function and leads to secondary diabetic complications. ALR2 inhibitors are a novel target for the treatment of retinopathy (cataract) influenced by diabetes. Epalrestat (stat), an ALR2 inhibitor, is the only drug candidate that was approved in the last four decades; the other drugs from the stat class were retracted after clinical trial studies due to untoward iatrogenic effects. The present study summarizes the recent development (2014 and onwards) of this pharmacologically active ALR2 heterocyclic scaffold and illustrates the rationale behind the design, structure-activity relationships, and biological studies performed on these molecules. The aim of the current review is to pave a straight path for medicinal chemists and chemical biologists, and, in general, to the drug discovery scientists to facilitate the synthesis and development of novel ALR2 inhibitors that may serve as lead molecules for the treatment of diseases related to the ALR2 enzyme.diabetic-related complications (cataract), novel heterocyclic scaffolds, structure-activity relationship studies, synthetic aldose reductase 2 inhibitors | INTRODUCTIONDiabetes mellitus (DM) is an autoimmune metabolic disorder mainly characterized by hyperglycemia which occurs due to impairment in normal blood glucose homeostasis. In DM, there is either no secretion of insulin by the islet of pancreatic β cells or diminished response to glucose by secreted insulin in the body. [1] Diabetes is of two types that is, insulin-dependent diabetes mellitus and insulin-independent diabetes mellitus also termed type 1 and type 2 DM, respectively. Pathophysiological conditions that induce DM include autoimmune imbalance, hormonal as well as the sedentary lifestyle of an individual, additionally urbanization, and exposure to harmful chemicals are other causes of disease. [2] Blood glucose homeostasis is regulated by several hormones. However, insulin and glucagon predominantly performed aforesaid functions. [3] Insulin reduces excess blood sugar levels either by inhibiting glucose synthesis by the liver or by increasing peripheral glucose utilization through the liver, skeletal muscles, and adipose tissues.

show abstract

Current literature in diabetes

2008

Diabetes Metabolism Res

View full text Add to dashboard Cite

show abstract

Comparison of Oral Insulin Spray and Subcutaneous Regular Insulin at Mealtime in Type 1 Diabetes

Cited by 21 publications

References 10 publications

Efficacy and safety of oral insulin compared to subcutaneous insulin: a systematic review and meta-analysis

Efficacy and safety of oral insulin compared to subcutaneous insulin: a systematic review and meta-analysis

Strategies in synthetic design and structure–activity relationship studies of novel heterocyclic scaffolds as aldose reductase‐2 inhibitors

Current literature in diabetes

Contact Info

Product

Resources

About